OMB APPROVAL
---------------------------
OMB Number: 3235-0191
Expires: February 28, 1994
Estimated average burden
hours per form. . . . 0.33
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-C
REPORT BY ISSUER OF SECURITIES QUOTED ON NASDAQ
INTERDEALER QUOTATION SYSTEM
FILED PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
AND RULE 13A-17 OR 15D-17 THEREUNDER
Interneuron Pharmaceuticals, Inc.
- -------------------------------------------------------------------------------
(Exact name of issuer as specified in charter)
One Ledgemont Center, 99 Hayden Avenue, Suite 340, Lexington, MA 02173
- -------------------------------------------------------------------------------
(Address of principal executive offices)
Issuer's telephone number, including area code (617) 861-8444
----------------
I. CHANGE IN NUMBER OF SHARES OUTSTANDING
Indicate any change (increase or decrease) of 5% more in the number of shares
outstanding:
1. Title of security COMMON STOCK, $.001 PAR VALUE
--------------------------------------------------
2. Number of shares outstanding before the change 37,187,003
---------------------
3. Number of shares outstanding after the change 40,539,658
-----------------------
4. Effective date of change JUNE 7, 1996
--------------------------------------------
5. Method of change:
Specify method (such as merger, acquisition, exchange, distribution,
stock split, reverse split, acquisition of stock for treasury, etc.)
ISSUANCE
---------------------------------------------------------------------
Give brief description of transaction PUBLIC OFFERING AND EXERCISE
-----------------------------
OF OUTSTANDING OPTIONS AND WARRANTS
----------------------------------------------------------------------
II. CHANGE IN NAME OF ISSUER
1. Name prior to change
---------------------------------------------------
2. Name after change
------------------------------------------------------
3. Effective date of charter amendment changing name
---------------------
4. Date of shareholder approval of change, if required
-------------------
Date JUNE 3, 1996 /S/ GLENN L. COOPER
---------------- -----------------------------
(Officer's signature & title)
Glenn L. Cooper, M.D., President and
Chief Executive Officer
-1-
